CureVac (CVAC) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
CureVac, a biopharmaceutical company, has reached a new licensing deal with GSK for up to €1.45 billion, signaling strong confidence in its mRNA technology platform. The company is also streamlining operations with a 30% workforce reduction to prioritize its focus on oncology and infectious diseases, while extending its cash runway into 2028. Furthermore, CureVac is advancing its glioblastoma vaccine candidate, CVGBM, into further clinical studies.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
